Publications:98
Carmen Argmann, PhD
About Me
Dr. Argmann has a doctorate from the faculty of Science at the University of Western Ontario, Canada where she showed that PPARγ and LXR activation could dramatically reduce macrophage foam cell formation, a key event in atherosclerosis. During her postdoctoral studies at the Institut de Génétique et de Biologie Moléculaire et Cellulaire in Strasbourg, France she contributed to the development of high-throughput mouse metabolic phenotyping protocols and demonstrated that resveratrol, a compound found in red wine, improves mitochondrial function and protects against metabolic disease in vivo.
As a research scientist in Dr Schadt’s genetics group at Rosetta Inpharmatics she contributed to the designing of large-scale genetic mouse crosses to address novel facets of metabolic disease. She was involved in integrating DNA variation, gene expression, and clinical data collected, in order to uncover core networks associated with metabolic disease processes, which in turn were used to identify novel therapeutic targets for the Diabetes and Obesity franchise.
In 2010, during her time in Dr. Aerts’s lab at the Academic Medical Center of the University of Amsterdam, she developed further into an integrative biologist. Her main focus has become applying novel integrative systems biology approaches to understand the hallmarks and key drivers of various human diseases.
Since 2013, she has been an assistant professor at Mount Sinai in the Department of Genetics and Genomic Sciences and is actively applying her integrative biology approaches in various large scale collaborations associated with: generating network models in inflammatory bowel disease; finding novel human beta cell regeneration strategies for Type 2 Diabetes and uncovering genetic modifiers of screenable inborn errors of metabolism. She is also a faculty member of the Icahn Genomics Institute.
Figure: Example schema of the integrative approaches applied to understanding disease processes.
Currently we have one postdoctoral position available. Please contact me at carmen.argmann@mssm.edu
Language
English
Position
ASSOCIATE CLINICAL PROFESSOR | Genetics and Genomic Sciences
Multi-Disciplinary Training Areas
Genetics and Genomic Sciences [GGS]
Video
Education
PhD, University of Western Ontario
Research
Identifying novel biological insights on complex human diseases requires spanning both the biological and computational worlds. Our biological data mining strategies aim to do this by helping to ask the right computational questions in order to get the right biological answers.
One major part of our group’s research is to facilitate generation of large scale datasets which can be integrated into causal predictive molecular networks which we then interpret for the pathophysiology of underlying complex biological questions. Our network insights are refined into candidate genes and pathways and formulated into testable hypotheses, some of which we perform experimental validation of ourselves.
Ultimately we aim to use this knowledge to predict novel therapeutic candidates for diseases of interest. We have applied these methods in multiple disciplines covering complex diseases (metabolic syndrome, IBD and cancer), complex traits (aging) as well as inborn errors of metabolism (Gaucher’s disease and Mitochondrial disorders).
Our system biology approaches are highly collaborative projects as they require various expertise from clinicians in the clinic, to experimentalist in the wet lab to the computational analyst in the dry lab. Three of my group’s main projects are summarized:
Publications
Selected Publications
- A Collection of Patient-Derived Intestinal Organoid Lines Reveals Epithelial Phenotypes Associated with Genetic Drivers of Pediatric Inflammatory Bowel Disease. Zahra Shojaei Jeshvaghani, Carmen Argmann, Maaike H. De Vries, Johan H. Van Es, Lauren V. Collen, Daniel Kotlarz, Mia Sveen, Phillip H. Comella, Scott B. Snapper, Christoph Klein, Eric E. Schadt, Hans Clevers, Michal Mokry, Ewart Kuijk, Edward Nieuwenhuis. Inflammatory Bowel Diseases
- Mild Crohn's Disease Is Associated With Altered Sphingolipid Metabolism and Reduced Neutrophilic Inflammation. Arno R. Bourgonje, Susanne Ibing, Palak Rajauria, Jellyana Peraza, Ashwin N. Ananthakrishnan, Carmen Argmann, Marla C. Dubinsky, Henrik A. Jacobsen, Tine Jess, Lone Larsen, Bernhard Y. Renard, Bruce E. Sands, Samir A. Shah, Jason M. Shapiro, Mayte Suarez-Fariñas, Jean Frédéric Colombel, Ryan C. Ungaro. Gastroenterology
- Disease duration impacts intestinal gene expression profiles in Crohn's disease but not in ulcerative colitis. Susanne Ibing, Christopher Tastad, Bernhard Y. Renard, Louis J. Cohen, Carmen Argmann, Drew Helmus, Eric E. Schadt, Miriam Merad, Anjli Kukreja, Sudha Visvanathan, Bruce E. Sands, Marla Dubinsky, Mayte Suarez-Fariñas, Jean Frédéric Colombel, Erwin P. Böttinger, Judy H. Cho, Francesca Petralia, Ryan C. Ungaro. Journal of Crohn's and Colitis
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Dr. Argmann has not yet completed reporting of industry relationships or has no industry relationships to report.
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.